The US Food and Drug Administration has declined to approve the generic drug leucovorin for autism, despite claims by the Trump administration that it could help hundreds of thousands of children with autism. However, senior FDA officials stated they found little evidence for expanding the drug's use to autism and narrowed its review to the treatment of a rare genetic condition.